MoneyWorks4Me

Indoco Remedies informs about company updates

18 Jan 2019 Evaluate

Indoco Remedies has informed that, as informed in its quarterly MDA Synpsis, the Company was expecting re-inspection of Goa Plant I and Plant II by USFDA. Inspection of Goa PIant II (Sterile facility) was completed from 14 - 21 November, 2018 and Goa Plant I (Solid oral facility) inspection by USFDA has commenced since 17th January, 2019.

The above information is a part of company’s filings submitted to BSE.

Indoco Remedies Share Price

221.60 -0.25 (-0.11%)
07-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1949.00
Dr. Reddys Labs. 1172.00
Cipla 1472.00
Lupin 2360.00
Zydus Lifesciences 1115.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: